BIOR Biora Therapeutics, Inc.
Biora Therapeutics Inc, formerly Progenity Inc is a biotechnology company engaged in developing oral biotherapeutics. Its drug-device combinations could enable new treatment approaches in the delivery of therapeutics in two main areas: Targeted delivery of therapeutics to the site of disease in the gastrointestinal ("GI") tract, which is designed to improve outcomes for patients with Inflammatory Bowel Disease (IBD); and Systemic delivery of biotherapeutics, which are designed to replace injection with needle-free, oral delivery technology. Geographically, it operates only in the United States. It generates revenue from providing molecular laboratory tests to customers.
$2.81 +0.07 (2.56%)
As of 03/27/2023 13:32:31 EST IEX book CBOE book
Security Information
Category1: US Equity
Category2: Common stocks
Category3: Small cap
GICS sector: Health Care
Industry: Biotechnology
Index country: USA
Country of incorporation:
IPO date: 06/19/2020
Outstanding shares: 223,170,617
Average volume: 132,142
Market cap: $642,731,377
Current dividend yield: 0.00%
All SEC filings: SEC Edgar Online
Quarterly filings: 10-Q
Annual filings: 10-K
Sedol:
Valuation (See tab for details)
PE ratio: 0.00
PB ratio: 0.00
PS ratio: 0.00
Return on equity: 0.00%
Net income %: 0.00%